Search

Designing ophthalmology services Part 3: How do we address the queues post‑COVID-19?

Part 1 of this series available herePart 2 of this series available here There is going to be enormous demand on ophthalmology services as they start to welcome patients back. The authors explain how modelling can help make the most...

Mucormycosis: In conversation with Dr Deepak Haldipur and Dr Aditya Moorthy

COVID-19 has ravaged the world in the past 18 months. The second wave in many countries was deadlier than the first. Mucormycosis, infamously labelled ‘the black fungus’ has affected some countries, such as India, in epidemic proportions within this COVID...

Adaptive optics imaging: resolving single cells in the living eye

The human retina is unique in the central nervous system (CNS) in that it can be directly visualised non-invasively. Technological advances of several imaging modalities, including optical coherence tomography (OCT), multichannel scanning laser ophthalmoscopy (SLO) and fundus photography, have afforded...

Pharmacopoeia of the Royal Infirmary of Edinburgh

The compact volume depicted in Figure 1 bears the simple title Pharmacopoeia. The book originally belonged to the author’s father, the late John King. A pharmacist by profession, John King maintained a keen interest in matters pertaining to pharmaceutical history....

An introduction to research governance

Research is the process of acquiring new generalisable knowledge and should be fully integrated into health care work. There is a growing drive to encourage and further develop evidence-based practice in ophthalmology so that staff and patients benefit from improved...

My top five: Innovative approaches to dry AMD

Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in the developing world with its prevalence rising alongside age. In societies characterised by ageing populations, it is imperative we explore more effective treatment to alleviate the...

Gene therapy for inherited retinal disease: the Manchester Ocular Gene Therapy Group MDT service

The authors describe the process set up in Manchester for the optimum delivery and assessment of a new gene therapy treatment for patients with RPE65 IRD. Inherited retinal dystrophies (IRDs) are the second commonest cause of severe visual impairment in...